The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Phase I trial investigating CD8-depleted HLA-mismatched unrelated DLI in patients with MDS and AML
Hany Elmariah, MD, MS, Moffitt Cancer Center, Tampa, FL, describes the structure and findings of a study that examined the use of induction chemotherapy and CD8-depleted HLA-mismatched unrelated donor lymphocyte infusion (DLI) in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Results demonstrated that this novel cellular therapy approach was well tolerated, with no dose-limiting toxicities observed. Dr Elmariah highlights that future studies with larger patient cohorts are needed to confirm these observations and further evaluate the efficacy of this approach. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Bristol Myers Squibb: Research Funding.
